BioCentury
ARTICLE | Company News

Takeda, Zinfandel in AD biomarker deal

January 12, 2011 1:58 AM UTC

Zinfandel Pharmaceuticals Inc. (Durham, N.C.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, worldwide rights to develop and commercialize an assay to detect variants of the translocase of outer mitochondrial membrane 40 homolog ( TOMM40; TOM40) gene. The companies will attempt to prospectively validate TOMM40 as a biomarker of risk for developing Alzheimer's disease in high-risk, older adults with normal cognition. The partners also will use the assay to identify candidates for clinical trials to evaluate the utility of Takeda's pioglitazone in AD. Zinfandel will receive $9 million up front and is eligible for up to $78 million in development milestones, plus commercial milestones and royalties. ...